The Safety of Intravenous Iron Dextran (Dexferrum®) During Hemodialysis in Patients with End Stage Renal Disease

The Safety of Intravenous Iron Dextran (Dexferrum®) During Hemodialysis in Patients with End Stage Renal Disease


Identification: nnj_jf00A2
Issue: January-February 2000
Volume: Vol. 27, No. 1

Standard: $30.00

Description

This article is available to members for free.

Note: Supported in part by American Regent Laboratories, Inc.

Author(s)

Credits

Credits: None available.

You must be logged in and own this product in order to post comments.

Print Certificate
Completed on: token-completed_on
Print Transcript
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content

References